LFCR (Lifecore Biomedical) FCF Margin % : -16.33% (As of Aug. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lifecore Biomedical's Free Cash Flow for the three months ended in Aug. 2024 was $-4.0 Mil. Lifecore Biomedical's Revenue for the three months ended in Aug. 2024 was $24.7 Mil. Therefore, Lifecore Biomedical's FCF Margin % for the quarter that ended in Aug. 2024 was -16.33%.

As of today, Lifecore Biomedical's current FCF Yield % is -3.09%.

The historical rank and industry rank for Lifecore Biomedical's FCF Margin % or its related term are showing as below:

LFCR' s FCF Margin % Range Over the Past 10 Years
Min: -47.21 Med: -6.92 Max: 1.69
Current: -6.84

During the past 13 years, the highest FCF Margin % of Lifecore Biomedical was 1.69%. The lowest was -47.21%. And the median was -6.92%.

LFCR's FCF Margin % is ranked worse than
68.01% of 994 companies
in the Drug Manufacturers industry
Industry Median: 0.9 vs LFCR: -6.84

Lifecore Biomedical FCF Margin % Historical Data

The historical data trend for Lifecore Biomedical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical FCF Margin % Chart

Lifecore Biomedical Annual Data

Trend

May15

May16

May17

May18

May19

May20

May21

May22

May23

May24

FCF Margin %

Get a 7-Day Free Trial

-27.32

-8.68

-47.21

-37.69

-14.14

Lifecore Biomedical Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
FCF Margin %	Get a 7-Day Free Trial															-54.58	-9.86	-21.80	15.84	-16.33

Competitive Comparison of Lifecore Biomedical's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lifecore Biomedical's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's FCF Margin % falls into.

Lifecore Biomedical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lifecore Biomedical's FCF Margin for the fiscal year that ended in May. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: May. 2024 )	/	Revenue (A: May. 2024 )
	=	-18.138	/	128.261
	=	-14.14 %

Lifecore Biomedical's FCF Margin for the quarter that ended in Aug. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Aug. 2024 )	/	Revenue (Q: Aug. 2024 )
	=	-4.035	/	24.705
	=	-16.33 %

Lifecore Biomedical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website

https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Executives

Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Christopher S Kiper	director	12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Raymond T. White	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Raymond H Diradoorian	director	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter	director	C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg	officer: Chief Financial Officer	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles	director	CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall	officer: Executive Vice President	3515 LYMAN BLVD., CHASKA MN 55318